Chris Evans holds the Robert Lovett Chair of Orthopaedic Surgery at Harvard Medical School, where he is also director of the Center for Molecular Orthopaedics. He obtained a B.S. in Genetics & Microbiology, a Ph.D. in Biochemistry, and a D.Sc. degree from the University of Wales, Great Britain, as well as a M.A. in the History & Philosophy of Science from the University of Pittsburgh.



Dr. Evans undertakes translational research devoted to the development of clinically useful gene therapies for arthritis and the regeneration of orthopaedic tissues, especially bone and cartilage. Together with Paul Robbins, he developed the first clinical protocol for the gene therapy of a non-lethal disease, rheumatoid arthritis, and completed a successful phase I trial.



Dr. Evans’s research has been recognized by a number of major awards, including the Kappa Delta Award of the American Academy of Orthopaedic Surgeons, the Henry Kunkle Award of the American College of Rheumatology, the Osteoarthritis Research Prize of The Osteoarthritis Research Society International, and, together with Paul Robbins, the International Orthopaedic Research Prize of the Synos Foundation. He is a Fellow of both the Royal Society of Chemistry and the Royal College of Pathologists, and President-Elect of the Orthopaedic Research Society.